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A B S T R A C T
Leber's hereditary optic neuroretinopathy (LHON) is manifested as a bilateral acute or subacute loss of central vision
due to optic atrophy. It is linked to point mutations of mitochondrial DNA, which is inherited maternally. The most com-
mon mitochondrial DNA point mutations associated with LHON are G3460A, G11778A and T14484C. These mutations
are linked with the defects of subunits of the complex I (NADH-dehydrogenase-ubiquinone reductase) in mitochondria.
The G11778A mitochondrial DNA point mutation is manifested by a severe visual impairment. In this paper two Cro-
atian families with the LHON G11778A mutation are presented. Three LHON patients from two families were younger
males which had the visual acuity of 0.1 or below, the ophthalmoscopy revealed telangiectatic microangiopathy and
papilloedema, while Goldmann kinetic perimetry showed a central scotoma. The mothers and female relatives were
LHON mutants without symptoms, whereas their sons suffered from a severe visual impairment. Molecular diagnosis
helps to explain the cause of LHON disease.
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Introduction
Leber's hereditary optic neuroretinopathy (LHON) is
manifested as a bilateral acute or subacute loss of central
vision due to optic atrophy. LHON at first affects one eye,
and central vision is lost in that eye over a period of a few
weeks. One or two months later, the second eye is af-
fected. The time when the affected person is loosing the
eyesight is the acute stage of LHON. Typical funduscopic
finding in the acute stage of LHON is a peripapillary
microangiopathy, damage to the optic nerve and the ret-
ina. A visual defect is usually the only clinical manifesta-
tion. However, it can be associated with cardiac conduc-
tion abnormalities (pre-excitation syndrome), peripheral
neuropathy and/or ataxia1,2.
Mitochondria are organelles responsible for energy
production by oxidative degradation of carbon substrates
into water and oxygen through the respiratory chain.
These reactions are catalyzed by respiratory chain com-
plexes I, II, III, and IV embedded in the inner mem-
brane of the mitochondria. The mitochondrial DNA is
16569 base pairs long. It contains a double-stranded
DNA molecule, no introns and replicates independently
of the nuclear genome. Mitochondrial DNA is maternally
inherited1,3. Defects of the mitochondrial DNA are large
scale rearrangements with single deletions or duplica-
tions. Over 118 point mutations of mitochondrial DNA
are known today4, associated with varying clinical phe-
notypes1,3,5.
Among the diseases associated with defects of mito-
chondrial DNA, LHON was first linked to point muta-
tions of the mitochondrial DNA1,6. Today, LHON is linked
to more than 30 point mutations of the mitochondrial
DNA (www.mitomap.org). The most common LHON
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point mutations are G3460A, G11778A and T14484C1,2.
The point mutation G3460A is associated with a func-
tional defect in ND1 subunit1,2, G11778A with a func-
tional defect in ND4 subunit1,6 and T14484C with a func-
tional defect in ND6 subunit1,7 of the respiratory chain
complex I.
The disease usually begins in the second or third de-
cade of life, with male predominance1,2,6,7. The average
onset of LHON is at 24.3 years of age among males, at
31.8 years among females8. However, there is also a case
report of a 6-year-old girl with LHON9. The point muta-
tion G11778A has a poor prognosis1,2,6 while T14484C is
linked to a mild course of the disease1,2,7. Spontaneous re-
covery from LHON was described in 5 out of 136 pa-
tients7.
This work is the first study of Croatian LHON fami-
lies using molecular diagnosis for the most common
LHON mitochondrial DNA point mutations.
Materials and Methods
Patients
24 persons from five families were included in this
study. Bilateral loss of vision was the criterion for diag-
nostic analysis including the tests for the mitochondrial
DNA mutations. The maternal line of inheritance was
followed while testing relatives. Consent of the patients
and of their relatives was obtained for the DNA analysis.
Ophthalmologic examinations
A complete ophthalmologic examination was conduct-
ed on patients with visual impairment. The examination
included best-corrected visual acuity using Snellen charts,
color vision with Ishihara plates, ophthalmoscopy, Gold-
mann kinetic and/or automated perimetry. Detailed fam-
ily anamnesis was recorded.
Other examinations
Computed axial tomography (CAT) scan and mag-
netic resonance imaging (MRI) with and without con-
trast were done for LHON patients.
Routine hematological and biochemical analyses of
blood and urine analysis were performed.
DNA testing from peripheral blood lymphocytes
using the PCR-RFLP method
DNA was isolated from peripheral blood lymphocyt-
es10. A polymerase chain reaction (PCR) was performed
for each point mutation separately using the specific set
of primers. The positions of primers in the sequence of
the mitochondrial genome (Cambridge sequence, www.mi-
tomap.org) were fw 5’ 3150 and rv 3’ 3600 for the
G3460A mutation, fw 5’ 11680 and rv 3’ 12000 for the
G11778A mutation and fw 5’ 14450 and rv 3’ 14608 for
the T14484C mutation. The PCR reaction was perfor-
med using the PCR Core Kit (Roche, Germany). The fi-
nal concentrations were: dNTP 0.2 mM, MgCl2 1.5 mM,
Taq DNA polymerase 0.03 U/L and primers 0.4 M.
PCR conditions were: initial denaturation 96 °C 2 min,
denaturation 94 °C 1 min, annealing 56 °C 1 min, exten-
sion 72 °C 1 min and final extension 72 °C 5 min, total 35
cycles. A GeneAmp PCR system 2400, Perkin Elmer, Ap-
plied Biosystems was used11. PCR products were verified
on 1.5% agarose gels. The PCR reaction was followed by
the restriction length fragment polymorphism method
(RFLP). PCR products were digested overnight at 37 °C
with restrictive enzymes, final concentration 25 U/mL.
For each point mutation a specific restrictive enzyme was
used: BsaH1 for G3460A12, SfaN1 for G11778A6 and Mbo
for T14484C (Bio Labs, New England). Restrictive frag-
ments were tested on 1.5% agarose gel using ethidi-
um-bromide for UV visualization of DNA. Both mutated
DNA as a positive control11 and wild-type DNA as a nega-
tive control were included in the analysis. In detection of
LHON mitochondrial DNA mutation G11778A, wild-
-type DNA was cut into two fragments in the PCR-RFLP
reaction, while mutated DNA was detected as one band,
no restriction. Restrictive fragments were analyzed by
Image Master VDS software 1.0 (Pharmacia) in order to
quantify the ratio of mutated and wild-type DNA for he-
teroplasmy.
Results
The most common three LHON mitochondrial DNA
point mutations G3460A, G11778A and T14484C were
tested in DNA samples of twenty four persons. Two fam-
ily cases with ten LHON G11778A mutants are pre-
sented in this paper.
Family No. 1
Four persons positive for the LHON G11778A mito-
chondrial DNA mutation were two patients 27 and 25
years of age, males with severe visual impairment (visual
acuity 0.01) and their mothers 50 and 53 of age with nor-
mal vision. The mothers were cousins (Figure 1). These
mutants were homoplasmic for the LHON G11778A mu-
tation.
Patient #1 (26 years old) was hospitalized at the Neu-
rology Department for a month in 2003 due to unilateral
loss of the right eye vision and papilloedema. Laboratory
analysis of blood and urine showed no pathological val-
ues. CAT scan and MRI with and without contrast re-
vealed no intracranial process. Visual evoked potential
revealed a suspicious neuronal lesion of the right visual
pathway and conduction disturbances in crossing fibers.
Brainstem evoked potential detected neuronal lesion of
the right auditory pathway. Somatosensory evoked po-
tentials of the median and tibial nerves were normal. Vi-
sion in his other eye was also lost within six months.
Ophthalmoscopy revealed telangiectatic microangiopa-
thy in the nerve fiber layer and papilloedema. Goldmann
kinetic perimetry revealed a central scotoma. As the pa-
tient had a second-degree male cousin (the mothers were
cousins) who also suffered from sudden visual loss in
both eyes eight years ago at the age of 17 (patient #2),
LHON disease was suspected. DNA testing revealed
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LHON G11778A mitochondrial point mutations in both
patients #1 and #2 and in their mothers (Figure 1). The
grandmother of patient #2 was heteroplasmic and ex-
pressed both wild type (80%) and mutated (20%) DNA in
peripheral blood lymphocytes (Figure 1).
Family No. 2
Six members of that family were carriers of the
LHON G11778A point mutation: patient #3, his mother
and sister, aunt, her daughter and the granddaughter
(Figures 2 and 3). Patient #3 was a 26 year old male ad-
mitted for clinical care in 1994, due to unilateral visual
loss in the right eye and papilloedema. Two months later
his left eye vision was lost as well. Best corrected visual
acuity in both eyes was 0.08 according to the Snellen
chart. Goldmann perimetry showed central scotomas but
no inner isopters. Ophthalmoscopy revealed bilateral
papilloedema. CAT scan showed no intracranial process.
Pulse steroid therapy was instituted but the recovery of
visual function was minimal (visual acuity improved
from 0.08 to 0.1). Standard hematological, biochemical
and immunological tests were within the normal range.
There were no cardial problems. Since the recovery of vi-
sual function with corticosteroid treatment was poor,
LHON disease was suspected. DNA testing turned to be
positive for the G11778A mitochondrial DNA point mu-
tation. The patient's sister, mother, aunt, aunt's daughter
and granddaughter were also LHON G11778A mutants,
but without visual impairment. All LHON G11778A in-
dividuals were homoplasmic, expressed only mutated
DNA. Except for the mother who had arterial hyperten-
sion, other family members had no signs of systemic dis-
eases, nor laboratory evidence of metabolic abnormali-
ties.
Discussion
This is the first Croatian pilot study of LHON linked
to a mitochondrial DNA point mutation. The mitochon-
drial DNA point mutation LHON G11778A was detected
in two families. Three young men (patients #1, #2, #3)
had a clinically manifested LHON disease. The mothers
and female relatives of these LHON patients were carri-
ers of the G11778A mitochondrial DNA mutation, hav-
ing neither visual impairment nor any other clinically
manifested disease. All LHON G11778A individuals pre-
sented in this paper were homoplasmic, except for one
grandmother in family No.1 who was heteroplasmic.
Heteroplasmy has also been described in LHON1,2 in 1
out of 7 individuals13. LHON cases in these two families
are in line with literature showing the preponderance of
LHON in young males having clinically manifested di-
sease1,2, 6–8.
These three most common LHON mitochondrial
DNA mutations investigated in our study were not de-
tected in other thirteen patients from three families hav-
ing optical neuropathy. Nevertheless, LHON may not be
completely excluded. Over 30 mitochondrial DNA point
mutations, linked to LHON and named secondary, have
been described (www.mitomap.org). This possibility should
be investigated further.
In this study no haplotype analysis of mitochondrial
DNA was made. LHON was linked most often to the J
haplotype of mitochondrial DNA1,14. In the Croatian pop-
ulation predominantly H15,16, U, J and T haplotypes of
mitochondrial DNA were detected15.






Fig. 1. Presentation of family No. 1 with LHON G11778A mito-
chondrial DNA mutation. LHON – Leber's hereditary optic neuro-
retinopathy, DNA-deoxyribonucleic acid. – females, not tested,
– males, not tested, – carriers of the mutation, mothers without
clinical symptoms, – patients with clinical symptoms, carriers






Fig. 2. Presentation of family No. 2 with LHON G11778A mito-
chondrial DNA mutation.. – females, not tested, – males, not
tested, – carriers of the mutation, female relatives without clin-
ical symptoms, – patient with clinical symptoms, carrier of the
mutation.
Fig. 3. Analysis of DNA from patient #3 with LHON mitochon-
drial point mutation G11778A and his female relatives. Lane 1 –
DNA standard, Lane 2 – patient, Lane 3 – patient's mother, Lane
4 – patient's aunt (mother's sister), Lane 5 – positive control,
Lane 6 – negative control, wild type (two restriction fragments of
222 and 98 bp), Lanes 2 – 5 reveal LHON G11778A mutation
seen as one band, no restriction.
Identification of LHON cannot be based solely upon
clinical diagnostic tests, a genetic analysis revealing the
maternally inherited mitochondrial DNA point mutation
should also be made. Joint efforts of ophthalmologists,
neurologists, other clinicians, biochemists and molecular
biologists are required for the diagnosis of LHON. Once
the diagnosis is established, genetic counseling of the
family becomes important1,10. A LHON prognosis is bet-
ter for female carriers of the mutated mitochondrial
DNA, who will not develop the clinically manifested dis-
ease.
No effective therapy is so far available for LHON, im-
proved nutrition is recommended. Gene therapy as an
experimental approach is not yet clinically relevant1.
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LEBEROVA NASLJEDNA OPTI^KA NEURORETINOPATIJA (LHON) VEZANA UZ TO^KASTU
MUTACIJU G11778A MITOHONDRIJSKE DNK U DVIJE HRVATSKE OBITELJI
S A @ E T A K
Leberova nasljedna opti~ka neuroretinopatija (LHON) manifestira se bilateralnim akutnim ili subakutnim gubit-
kom centralne vidne o{trine uslijed atrofije vidnog `ivca. LHON je vezan uz to~kaste mutacije mitohondrijske DNK i
naslje|uje se po majci. Naj~e{}e to~kaste mutacije mitohondrijske DNK vezane uz LHON jesu G3460A, G11778A i
T14484C. Ove mutacije vezane su uz defekte podjedinica kompleksa I (NADH-dehidrogenaza-ubikinon reduktaza) u
mitohondrijima. LHON G11778A to~kasta mutacija mitohondrijske DNK manifestira se te{kim o{te}enjem vida. U
ovom radu prikazane su dvije hrvatske obitelji s LHON G11778A mutacijom mitohondrijske DNA. Tri LHON bolesnika
iz dvije obitelji mlade su mu{ke osobe u kojih vidna o{trina iznosi 0.1 ili manje, oftalmoskopija je otkrila telangiek-
tati~nu mikroangiopatiju i edem papile vidnog `ivca, dok je kvantitativna kineti~ka Goldmannova perimetrija pokazala
su`enje uz centralne skotome. Majke i `enski pripadnici obitelji su LHON G11778A mutanti bez simptoma, a sinovi
LHON G11778A mutanti imaju te{ka o{te}enja vida. Molekularna dijagnoza poma`e u obja{njenju uzroka LHON bo-
lesti.
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